Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The effect of lifestyle treatment on childhood obesity
ISRCTN ISRCTN36146436
ClinicalTrials.gov identifier
Public title The effect of lifestyle treatment on childhood obesity
Scientific title A randomised controlled trial evaluating the effect of family-based multidisciplinary cognitive behavioural treatment in children with obesity
Acronym Haagse Maatjes
Serial number at source 06-091
Study hypothesis During the last three decades the prevalence of childhood obesity has increased dramatically in western countries, including the Netherlands. The rapidly increasing prevalence of childhood obesity seen during the last few decades, is mostly the result of an increased food consumption and a change from a more physically active lifestyle to a more sedentary one. The consequence of the increased prevalence of childhood obesity is the earlier appearance of co-morbidities.

The primary aim of this study is the effect evaluation of a family-based multidisciplinary cognitive behavioural treatment on obesity (expressed as body mass index [BMI]-standard deviation score [SDS]) compared to standard care (advice on increased physical activity and dietary changes) in children with obesity. The secondary aim of the study was to investigate the effect of this treatment on changes in waist circumference, insulin sensitivity, inflammation, secretion of gastrointestinal hormones and changes in physical fitness and quality of life, compared to standard care. Furthermore, we aimed at assessing the long-term effects and possible predictive factors for response treatment.
Lay summary Not provided at time of registration
Ethics approval The Dutch National Medical Ethical Committee approved on the 13th of February 2007 (ref: METC-nr. 06-091)
Study design Longitudinal single centre single blind randomised clinical trial, with stratification for gender and ethnicity
Countries of recruitment Netherlands
Disease/condition/study domain Childhood obesity
Participants - inclusion criteria 1. Age 8-17 years (at baseline)
2. Obesity based on BMI values defined by Cole et al.
3. Children/ adolescents presented to the paediatrician
4. Written informed consent from parents and children
Participants - exclusion criteria 1. Insufficient knowledge/understanding of the Dutch language
2. Children/adolescents following special education
3. Serious co-morbidity
4. Obesity caused by a syndrome (like Prader Willi, Laurence-Moon-Biedl)
5. Endocrine cause of obesity (like hypothyreoidy, Cushing)
6. Obesity caused by medication (like high dose of glucocorticoids)
7. Parents and children/adolescents not willing to invest 40 hours in the treatment
8. Children/adolescents with diabetes mellitus
9. Children/adolescents who already followed a multidisciplinary treatment, including psychological treatment and intensive parent involvement
Anticipated start date 13/03/2007
Anticipated end date 30/09/2010
Status of trial Completed
Patient information material Not available in web format, please use contact details below to request a patient information sheet
Target number of participants 35 per group, 70 in total
Interventions The cognitive behaviour treatment program takes two years, with an intensive phase of three monthsat the beginning, followed by booster sessions. In the screening phase the children with their parents were seen at two separate occasions individually by a dietitian, a child-physiotherapist, a child-psychologist and a social worker. In this way individual family situations which could interfere with the treatment are evaluated and expectations of the program are checked. During the intensive phase of the program the experimental group is offered 7 group meetings of 2 1/2 hours and the parents are offered 5 separate parent meetings and 1 meeting together with the children. The control group is given an initial physical activity and nutritional advice. The control group is offered to participate in the treatment after 12 months. The normal weight control group is measured only once. A person blinded for the study design measures weight and height at baseline.
Primary outcome measure(s) Do children (8-17 yr.) with obesity show a significant decrease (> 0.5 BMI-SDS) in BMI (as defined by Cole et al.[2]) after 3 months of intensive treatment compared to children who were given advice on increased physical activity and dietary changes?
Secondary outcome measure(s) 1. Do children with obesity have a significantly more beneficial effect of 3 months intensive treatment compared to standard care on changes in waist circumference, insulin sensitivity, secretion of gastrointestinal hormones, cardiovascular fitness and quality of life?
2. Will the hypothesized beneficial effects of 3 months intensive treatment in children with obesity persist after 12 and 24 months of follow-up?
3. Are the genetic background of the children, the level of parental education, the social economic status or the ethnicity predictive variables for the degree of obesity in these children, and for the success of treatment?
Sources of funding Juliana Children's Hospital, HagaHospital (Netherlands) - unrestricted educational grand
Trial website
Publications 2011 protocol in http://www.ncbi.nlm.nih.gov/pubmed/21548919
Contact name Dr  Mieke  Houdijk
  Address Sportlaan 600
  City/town the Hague
  Zip/Postcode 2566 JM
  Country Netherlands
Sponsor Haga Teaching Hospital (HagaZiekenhuis) (Netherlands)
  Address c/o E.C.A.M. Houdijk
Sportlaan 600
  City/town the Hague
  Zip/Postcode 2566 JM
  Country Netherlands
Date applied 06/04/2010
Last edited 21/09/2011
Date ISRCTN assigned 13/07/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central